41996-98-9

Upstream product

• 13633-25-5 1-Bromo-4-phenylbutane 
• 75-36-5 acetyl chloride 
• 3360-41-6 4-phenyl-butan-1-ol 

Downstream Products

• 7377-04-0 4-(4-bromobutyl)benzoic acid 
• 1237521-94-6 3-(4-(4-acetylphenyl)butyl)-6-benzyl-5-isopropylpyrimidine-2,4(1H,3H)-dione 
• 97393-89-0 p-<4-Dimethylamino-butyl>-β-hydroxyimino-acetophenon 
• 92321-44-3 p-(4-Dimethylamino-butyl)-acetophenon 

Relevant academic research and scientific papers

Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase

Rational design of dually active inhibitors against human immunodeficiency virus (HIV) reverse transcriptase (RT) and integrase (IN) has proved viable with 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) type of non-nucleoside RT inhibitors (NNRTIs). To establish the pharmacophore and study the structure-activity relationships (SAR) of integrase inhibition within a previously disclosed RT/IN dual inhibitor scaffold, new analogues featuring substitution at different sites of the HEPT ring were designed and synthesized. These studies have revealed an IN inhibition pharmacophore that is merged with the known RT pharmacophore through a shared C-6 benzyl group. Further SAR also demonstrated that optimal IN inhibition within our dual inhibitor scaffold requires a regiospecific (N-1) diketoacid (DKA)-carrying pendant with a certain length.

Optically active ester derivatives, preparation process thereof, liquid crystal materials and a light switching element

Disclosed are herein optically active ester derivatives represented by the formula (I): STR1 (wherein R1 represents an alkyl group having 3 to 20 carbon atoms; R2 represents an optically active alkyl or alkoxyalkyl group having 3 to 15 carbon atoms optionally substituted by halogen atoms; Y represents --O--, --COO-- or --OCO--; X represents --COO-- or --OCO--; l represents a number of 1 or 2; k and m each represents a number of 0 or 1; n represents a number of 1 to 6), preparation processes therefor, liquid crystal materials containing such ester derivatives as active ingredient, and a light switching element using said liquid crystal materials as liquid crystal element.

Interphenylene 9-thia-11-oxo-12-aza-prostanoic acids

This invention relates to novel interphenylene 9-thia-11-oxo-12-azaprostanoic acid compounds, salts, and derivatives thereof. These compounds are exceptionally potent renal vasodilators and antihypertensives which are active when administered orally but which have a more specific type of biological activity than that of many of the natural prostaglandins and their synthetic analogs or derivatives.